Cargando…
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center
PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is challenging health systems all over the world. Cancer patients have a higher risk of being infected by SARS-Cov-2 and higher coronavirus disease 2019 (COVID-19) severity and mortality. Up to date, there were no data about COVID...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912964/ https://www.ncbi.nlm.nih.gov/pubmed/33638758 http://dx.doi.org/10.1007/s12020-021-02650-z |
_version_ | 1783656696052187136 |
---|---|
author | Prete, Alessandro Falcone, Marco Bottici, Valeria Giani, Carlotta Tiseo, Giusy Agate, Laura Matrone, Antonio Cappagli, Virginia Valerio, Laura Lorusso, Loredana Minaldi, Elisa Molinaro, Eleonora Elisei, Rossella |
author_facet | Prete, Alessandro Falcone, Marco Bottici, Valeria Giani, Carlotta Tiseo, Giusy Agate, Laura Matrone, Antonio Cappagli, Virginia Valerio, Laura Lorusso, Loredana Minaldi, Elisa Molinaro, Eleonora Elisei, Rossella |
author_sort | Prete, Alessandro |
collection | PubMed |
description | PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is challenging health systems all over the world. Cancer patients have a higher risk of being infected by SARS-Cov-2 and higher coronavirus disease 2019 (COVID-19) severity and mortality. Up to date, there were no data about COVID-19 in patients with thyroid cancer (TCs). The aim of the study was to describe the prevalence of COVID-19 in a well-characterized series of TC patients evaluated for the persistence of the neoplastic disease from March to September 2020; as secondary objective, we looked for the COVID-19 disease severity in a subgroup of multimetastatic TC patients. METHODS: We evaluated 1464 patients affected by persistent TC: 67 patients who were taking multikinase inhibitors (MKIs) and 1397 under active surveillance for a persistent but stable disease. During the clinical evaluation, all patients were specifically investigated about a positive history of Sars-Cov-2 infection. RESULTS: SARS-Cov-2 infection was identified in 4/1464 (0.3%) cases of patients affected by TC. We identified three cases among patients under active surveillance (0.2%), and one case among patients treated with MKI systemic therapy (1/67, 1.5%). This patient was taking vandetanib for metastatic medullary thyroid cancer (MTC), when he came to our attention referring severe fatigue, dyspnea for light physical activities. He presented a mild COVID-19 and he received exclusively supportive care. After a multidisciplinary consultation, we decided against the discontinuation of vandetanib. After 2 months from the infection, he did not present any signs of active infection, and the MTC metastatic disease was stable. CONCLUSIONS: We showed that COVID-19 is not more frequent in TC patients than in general population, although a relatively higher prevalence in the group of TC patients treated with MKIs. A single patient with advanced TC and SARS-Cov-2 infection during MKIs treatment had a mild COVID-19 and did not require the discontinuation of MKI therapy. In cases of more severe COVID-19, an accurate evaluation from a multidisciplinary team would consider risks and benefits in taking the decision to continue or stop MKI treatment. |
format | Online Article Text |
id | pubmed-7912964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-79129642021-03-01 Thyroid cancer and COVID-19: experience at one single thyroid disease referral center Prete, Alessandro Falcone, Marco Bottici, Valeria Giani, Carlotta Tiseo, Giusy Agate, Laura Matrone, Antonio Cappagli, Virginia Valerio, Laura Lorusso, Loredana Minaldi, Elisa Molinaro, Eleonora Elisei, Rossella Endocrine Original Article PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is challenging health systems all over the world. Cancer patients have a higher risk of being infected by SARS-Cov-2 and higher coronavirus disease 2019 (COVID-19) severity and mortality. Up to date, there were no data about COVID-19 in patients with thyroid cancer (TCs). The aim of the study was to describe the prevalence of COVID-19 in a well-characterized series of TC patients evaluated for the persistence of the neoplastic disease from March to September 2020; as secondary objective, we looked for the COVID-19 disease severity in a subgroup of multimetastatic TC patients. METHODS: We evaluated 1464 patients affected by persistent TC: 67 patients who were taking multikinase inhibitors (MKIs) and 1397 under active surveillance for a persistent but stable disease. During the clinical evaluation, all patients were specifically investigated about a positive history of Sars-Cov-2 infection. RESULTS: SARS-Cov-2 infection was identified in 4/1464 (0.3%) cases of patients affected by TC. We identified three cases among patients under active surveillance (0.2%), and one case among patients treated with MKI systemic therapy (1/67, 1.5%). This patient was taking vandetanib for metastatic medullary thyroid cancer (MTC), when he came to our attention referring severe fatigue, dyspnea for light physical activities. He presented a mild COVID-19 and he received exclusively supportive care. After a multidisciplinary consultation, we decided against the discontinuation of vandetanib. After 2 months from the infection, he did not present any signs of active infection, and the MTC metastatic disease was stable. CONCLUSIONS: We showed that COVID-19 is not more frequent in TC patients than in general population, although a relatively higher prevalence in the group of TC patients treated with MKIs. A single patient with advanced TC and SARS-Cov-2 infection during MKIs treatment had a mild COVID-19 and did not require the discontinuation of MKI therapy. In cases of more severe COVID-19, an accurate evaluation from a multidisciplinary team would consider risks and benefits in taking the decision to continue or stop MKI treatment. Springer US 2021-02-27 2021 /pmc/articles/PMC7912964/ /pubmed/33638758 http://dx.doi.org/10.1007/s12020-021-02650-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Prete, Alessandro Falcone, Marco Bottici, Valeria Giani, Carlotta Tiseo, Giusy Agate, Laura Matrone, Antonio Cappagli, Virginia Valerio, Laura Lorusso, Loredana Minaldi, Elisa Molinaro, Eleonora Elisei, Rossella Thyroid cancer and COVID-19: experience at one single thyroid disease referral center |
title | Thyroid cancer and COVID-19: experience at one single thyroid disease referral center |
title_full | Thyroid cancer and COVID-19: experience at one single thyroid disease referral center |
title_fullStr | Thyroid cancer and COVID-19: experience at one single thyroid disease referral center |
title_full_unstemmed | Thyroid cancer and COVID-19: experience at one single thyroid disease referral center |
title_short | Thyroid cancer and COVID-19: experience at one single thyroid disease referral center |
title_sort | thyroid cancer and covid-19: experience at one single thyroid disease referral center |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912964/ https://www.ncbi.nlm.nih.gov/pubmed/33638758 http://dx.doi.org/10.1007/s12020-021-02650-z |
work_keys_str_mv | AT pretealessandro thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT falconemarco thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT botticivaleria thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT gianicarlotta thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT tiseogiusy thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT agatelaura thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT matroneantonio thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT cappaglivirginia thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT valeriolaura thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT lorussoloredana thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT minaldielisa thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT molinaroeleonora thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter AT eliseirossella thyroidcancerandcovid19experienceatonesinglethyroiddiseasereferralcenter |